Focus Stocks
Trading Idea - Eli Lilly A Hammer Formed
Published on Wednesday, 24 October 2012 05:00 Written by TradersHuddle Wire
New York, October 24th (TradersHuddle.com) - Shares of Eli Lilly & Co. (NYSE:LLY) ended the trading session
lower by $0.37 or -0.71% from its previous close. Eli Lilly's price action in the session formed what is considered to be a Hammer, where bears drove prices lower intraday. However, the strong finish indicates that bulls regained control, forming a trend reversal.
Eli Lilly (NYSE:LLY) principal activities are to develop, manufacture and market pharmaceutical-based health care solutions. The company specializes in research and development, production and marketing of products for the treatment of diabetes worldwide, such as insulin and insulin delivery devices.. Some of the company's patents include Zyprexa, Prozac, Permax, Humulin, Evista, Humalog, Humatrope, Vancocin, Keflex, Nebcin , Lorabid, Gemzar, Tylan, and Rumensin.
Eli Lilly's stock has been trading in a well defined range with calculated support at $50.00 and resistance at $53.99. This range can be used by traders to plan their next moves.
Traders wanting to establish a position in Eli Lilly or traders that are already holding the stock can use the hammer formation to their advantage, since the pattern signal a potential bullish trend reversal.
The Hammer is an important candlestick pattern, as it can mark bottoms and support levels. Further buying pressure, and preferably on expanding volume, is needed before acting, as heavy volume will serve to confirm the validity of the reversal.
In the case of Eli Lilly, traders who want to add to their positions or start a new position, need to watch for confirmation of the reversal. Below a Hammer illustration:

Related Articles
- From Research Labs to Doctors' Offices, Health Care Providers at Lilly Play Important Role in Bringing New and Innovative Medicines to Patients
- Lilly Oncology to Release New Pipeline Data at ASCO 2013
- Lilly Provides Update on CEO Dr. John Lechleiter
- Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
- Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress
- Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
- Lilly Declares Second-Quarter 2013 Dividend
- Critical Alerts For Microsoft, Suncor Energy, Eli Lilly, TRW Automotive, and Embraer Released By InvestorsObserver
- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
- The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small
Related Partner Headlines
- Eli Lilly And Stock To Go Ex-dividend Tomorrow (LLY) - TheStreet.com
- Eli Lilly And Company Stock Buy Recommendation Reiterated (LLY) - TheStreet.com
- Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For Two Investigational Medicines to Treat Autoimmune Diseases - Benzinga
- Eli Lilly And Company (LLY): Today's Featured Drugs Laggard - TheStreet.com
- Eli Lilly: Bearish Optons Trade - TheStreet.com
- Eli Lilly And Company Stock Buy Recommendation Reiterated (LLY) - TheStreet.com
- Lilly to Announce Expansion of Indianapolis Insulin Manufacturing Operations - Benzinga
- European Commission Approves Lilly's Cialis for Benign Prostatic Hyperplasia - Benzinga
- Eli Lilly And Company (LLY): Today's Featured Drugs Laggard - TheStreet.com
- UPDATE: Eli Lilly Posts Downbeat Q3 Profit - Benzinga
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,335.28 Trade time:4:36PM EDT Value change:▼19.12 (-0.12%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,666.29 Trade time:4:36PM EDT Value change:▼1.18 (-0.07%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,496.43 Trade time:5:15PM EDT Value change:▼2.54 (-0.07%)In The Wires
-
CNO Financial Group Completes Amendment to Senior Secured Credit Facility -
Regal Beloit Corporation To Present At The KeyBanc Capital Markets' Industrial, Automotive and Transportation Conference -
Sherwin-Williams Unveils A Colorful Salute To Cleveland -
Carnival Corporation & plc Updates Earnings Guidance For Second Half Of 2013 -
AK Steel Joint Venture Completes $375 Million Financing For New Iron Ore Pellet Plant -
Krispy Kreme to Release Fiscal 2014 First Quarter Results and Discuss Management's Outlook for the Full Year on May 30, 2013 -
Sensata Technologies listed #7 in The Boston Globe's 2013 list of Top 100 best-performing companies -
Patheon Announces Date of Fiscal 2013 Second Quarter Financial Results








